MDXG at a glance
MIMEDX GROUP, INC. (MDXG, SEC CIK 1376339) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on October 28, 2026 and Form 4 insider filings as recently as July 7, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), MIMEDX GROUP, INC. (MDXG) reported revenue of $418.6 million (up 20.0% from FY2024) and net income of $48.6 million. Diluted EPS was $0.32.
- As of September 30, 2026, 31 institutional investment managers tracked by SignalX reported holding MIMEDX GROUP, INC. (MDXG) shares worth $185.1 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $418.6M
- +20.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 31 funds
- $185.1M · +0 vs prior quarter
- Latest 8-K
- Oct 28, 2026
- Item 2.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New regulatory risk: FTC Second Request received October 15, 2026, potentially extending HSR waiting period 30 days after substantial compliance
- New transaction risk: Sanara acquisition could face FTC-imposed conditions, restrictions, or prevention, reducing anticipated benefits
- New financing risk: Hayfin Term Loan availability depends on commitment conditions, with alternative financing potentially costlier
- New leverage risk: Expected Hayfin Term Loan may increase debt service and restrict additional borrowing, investments, dividends, and asset sales
- New operational risk: Acquisition-related review and integration could divert management resources and disrupt employees, customers, and business relationships
Management Discussion & Analysis
- Revenue $62.3M, down 45.2% YoY from $113.7M
- Gross margin 79.8% vs 83.5% YoY, pressured by Wound pricing and unfavorable mix
- Best segment Surgical revenue $40.0M, up 9.1%; worst Wound revenue $22.3M, down 71.0%
- Net cash $120.8M, up $2M sequentially; operating cash used $4.2M through nine months
- Near-term headwinds: Medicare reimbursement changes and FTC Second Request delaying Sanara acquisition clearance
AI summary of the MDXG 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.3: Item EX-99.3
- Proposed Sanara acquisition values target at approximately $350 million, funded partly by a $300 million term loan and 4.4 million MDXG shares
- Debt terms: six-year maturity at SOFR plus 6.25%, creating meaningful post-close interest and leverage exposure
Item EX-99.1: Item EX-99.1
- Q3 net sales $62.3M, down 45%, driven by Wound sales falling 71% despite Surgical sales growth of 9%
- Adjusted EBITDA $2.1M, margin 3.3%, versus $35.0M and 30.7% prior year, showing severe earnings pressure
Item EX-99.2: Item EX-99.2
- Q3 net sales $62MM, with Surgical $40MM and Wound $22MM
- Surgical volume growth reached mid-teens, while Wound Care Center volumes rose 7% sequentially and over 20% year-over-year
Item 2.02: Results of Operations and Financial Condition
- MiMedx announced second-quarter 2026 results on October 28, 2026
- Detailed financial results and management commentary are provided in Exhibit 99.1, the earnings press release
Item 7.01: Regulation FD Disclosure
- October 28, 2026 earnings call covering third-quarter 2026 financial and operating results
- Investor presentation updated October 28, 2026, offering supplemental operating and strategic information
Item 8.01: Other Events
- FTC issued a Second Request on October 15, 2026, extending the HSR antitrust waiting period
- Merger closing delayed until 30 days after substantial compliance, unless FTC terminates or parties extend the period
Item 7.01: Regulation FD Disclosure
- MiMedx announced entry into a merger agreement on July 29, 2026, with Sanara MedTech
- Investor presentation expected to outline transaction timing, synergies, combined surgical revenue and Adjusted EBITDA margin
Item 1.01: Entry into a Material Definitive Agreement
- MiMedx to acquire Sanara for $33.00 cash plus 0.4735 MiMedx shares per Sanara share, implying $35.00 total stated consideration
- $300.0 million first-lien senior secured term loan planned, increasing leverage and replacing MiMedx’s existing credit facility
AI summaries of MDXG 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MDXG
Don't miss the next MDXG filing
- Alerts as it files. A push when MDXG files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MDXG, by share count.
- Ask anything. An AI agent that reads every MDXG filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| DOUG RICE | F | Jul 2, 2026 | 12,749 | $3.95 |
| Maersk-Moller Kimberly | F | Jun 24, 2026 | 19,820 | $3.83 |
| PUHY DOROTHY E | A | Jun 10, 2026 | 50,913 | $3.64 |
| HAWKINS WILLIAM A | A | Jun 10, 2026 | 50,913 | $3.64 |
| Olson Tiffany | A | Jun 10, 2026 | 50,913 | $3.64 |
| BIERMAN JAMES L | A | Jun 10, 2026 | 50,913 | $3.64 |
| Newton Todd | A | Jun 10, 2026 | 50,913 | $3.64 |
| Maersk-Moller Kimberly | F | Mar 13, 2026 | 6,762 | $4.38 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $348.9M | $418.6M |
| Gross Profit | - | $288.8M | $345.6M |
| Operating Income | $37.1M | $58.9M | $63.9M |
| Net Income | $58.2M | $42.4M | $48.6M |
| Gross Margin | - | 82.8% | 82.6% |
| Op. Margin | - | 16.9% | 15.3% |
| Net Margin | - | 12.2% | 11.6% |
| Balance Sheet | |||
| Total Assets | $239.0M | $263.9M | $342.7M |
| Equity | - | $193.1M | $256.5M |
| ROE | - | 22.0% | 18.9% |
| Per Share | |||
| EPS | - | $0.28 | $0.32 |
| Cash Flow | |||
| Operating CF | - | $66.2M | $74.0M |
| CapEx | $2.0M | - | - |
Source: XBRL data in MIMEDX GROUP, INC. (MDXG)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate MDXG share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 31 | $185.1M |
| Q2 2026 | 31 | $154.5M |
| Q1 2026 | 30 | $146.2M |
| Q4 2025 | 28 | $238.8M |
| Q3 2025 | 30 | $253.7M |
| Q2 2025 | 30 | $221.8M |
| Q1 2025 | 29 | $177.0M |
| Q4 2024 | 24 | $178.5M |
- Two Sigma Investments+1.00M (+407%)
- BlackRock+852.9K (+7%)
- Prudential Financial+182.1K (+404%)
- Citadel Advisors LLC+102.7K (+12%)
- Dimensional Fund Advisors+102.3K (+5%)
- State Street Corp−1.17M (-21%)
- Goldman Sachs Group−863.1K (-32%)
- D.E. Shaw & Co−225.7K (-54%)
- Franklin Resources−158.2K (-64%)
- AQR Capital Management−141.5K (-6%)
- Millennium Management+230.0K
- FMR LLC (Fidelity)−152.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 233 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MDXG filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Oct 28, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 8-K | Oct 16, 2026 | - | Analysis | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 10-Q | Jul 29, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 10-Q | Apr 29, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 29, 2026 | - | Analysis | - |
| 8-K | Apr 16, 2026 | - | Analysis | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 12, 2026 | - | - | - |
| 4 | Mar 12, 2026 | - | - | - |
| 4 | Mar 12, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
| 4 | Mar 6, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
MDXG SEC filings: frequently asked questions
Which institutions hold MDXG stock?
As of September 30, 2026, the largest MIMEDX GROUP, INC. (MDXG) holders among the 13F filers tracked by SignalX were BlackRock ($60.6 million), Vanguard Capital Management LLC ($24.0 million), State Street Corp ($20.5 million), Renaissance Technologies LLC ($11.0 million), AQR Capital Management ($10.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MDXG's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), MIMEDX GROUP, INC. (MDXG) reported revenue of $418.6 million (up 20.0% from FY2024) and net income of $48.6 million. Diluted EPS was $0.32. The figures come from the XBRL data in the 10-K.
What did MDXG report in its latest 8-K?
MIMEDX GROUP, INC. (MDXG) filed an 8-K on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Proposed Sanara acquisition values target at approximately $350 million, funded partly by a $300 million term loan and 4.4 million MDXG shares.
What are the latest MDXG SEC filings?
MIMEDX GROUP, INC. (MDXG) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on October 28, 2026 and a Form 4 insider filing on July 7, 2026.
What is MDXG's SEC CIK number?
MIMEDX GROUP, INC. (MDXG)'s SEC Central Index Key (CIK) is 1376339. EDGAR lists every MDXG filing under that number.
Ask anything about MDXG
The research agent reads MDXG's filings, financials, insider trades and 13F holders, then answers with sources.